Introduction
There are many advantages to donor plateletpheresis. Among these are the following: economic use of blood due to selective collection of a relatively large amount of components, possibility of more frequent donations, elimination of unnecessary component separation in the laboratory, reduced donor exposures and therefore reduced risk of disease transmission and risk of human leukocyte antigen (HLA) alloimmunization, use as an effective treatment for already alloimmunized patients, and labeling as 'leukoreduced' without further manipulation [1] [2] [3] [4] [5] . Although improvements in apheresis technology are ongoing, some problems do remain, e.g. the duration of the procedure and donor discomfort owing to the citrate used for anticoagulation. Minimization of these variables is the driving motivation behind new apheresis instrument development. Presently, there are a variety of plateletpheresis instruments available on the market, and several studies focusing on the comparison of different plateletpheresis cell separators have been conducted [6] [7] [8] [9] [10] [11] [12] [13] . There is, however, no published data comparing the Fenwal Amicus and the Fresenius COM.TEC cell separators. In the present study, we compared plateletpheresis on the Fenwal Amicus cell separator (Baxter Healthcare, Deerfield, IL, USA) and the COM.TEC cell separator (Fresenius HemoCare GmbH, Bad Homburg, Germany) with respect to separation parameters and platelet (PLT) yield characteristics such as processing times, PLT yields, separation efficiencies, and white blood cell (WBC) content.
Materials and Methods
The study included all healthy volunteer donors between January 2006 and December 2006 who met the Council of Europe Guidelines and Recommendations for apheresis and the standard guidelines established by the American Association of Blood Banks [14, 15] . Criteria for eligibility for a single unit (≥3.3 × 10 11 ) were as follows: 1) age 18-60 years, 2) preapheresis peripheral blood (PB) PLT count ≥ 150 × 10 9 /l, 3) hemoglobin (Hb) level ≥ 13.5 g/dl, 4) donor body weight ≥ 50 kg, 5) negative tests for HIV, hepatitis B surface antigen, hepatitis C, and syphilis, 6) absence of any illness, 7) in good health and feeling well, 8) adequate venous accesses, 9) at least 3 months since last whole blood donation, 10) at least 3 days since last plateletpheresis, and 11) no consumption of non-steroidal antiinflammatory drugs and acetyl salicylic acid in the last 7 days [16] . The study was approved by the Institutional Review Board. Written consent was obtained after procedural risks were explained in detail before the procedure. Plateletpheresis donors were sequentially assigned to either the Baxter Amicus cell separator or the Fresenius COM.TEC device. Antecubital veins were used for the venipuncture in all the donors. Senior apheresis technicians performed all procedures. Vital signs were monitored at the beginning and end of each procedure; donors were also monitored for adverse events during the apheresis procedures. Pre-procedure donors' height, weight, sex, and total blood volume (TBV) were also recorded. None of the donors received routine prophylactic oral or intravenous calcium during the apheresis procedure.
Instruments
A single Fenwal Amicus instrument with software version 2.52 (Baxter Healthcare, Deerfield, IL, USA) was used. A double venous access with a plateletpheresis kit was used per the manufacturer's recommendation. The parameters of the Amicus device were as follows: whole blood flow 55-80 ml/min, interface set point 0.60, and anticoagulant/whole blood ratio 1:8-11. The second cell separator used for PLT collection was the blood cell separator COM.TEC, software version 4.0 (Fresenius HemoCare GmbH, Bad Homburg, Germany). Per the manufacturer's recommendations, we used a double venous access with a C5L kit in a dual-needle procedure (program PLT5d DN). The machine parameters were as follows: whole blood flow 50-75 ml/min, interface set point 33, and anticoagulant/whole blood ratio 1:8-12. The following data were entered into the cell separator program for both instruments: donors' height, weight, sex, hematocrit (Htc) and pre-apheresis PB platelet count. The processed blood volume to reach the target PLT yield (≥3.3 × 10 11 ) was determined by both instruments. No additional post-procedure processing or filtration to obtain leukoreduced products was performed on either instrument.
Peripheral Blood Variables
Peripheral blood samples (2 ml, ethylene diamine tetraacetate (EDTA)) were drawn from each donor prior to and 2 h after completion of apheresis. Pre-and post-apheresis complete blood count (CBC) analysis was performed. Donor PLT loss was analyzed using the following formula: PLT loss = (pre-PLT count -post-PLT count) × 100/pre-PLT count.
Operational Variables
We recorded all procedure times, the processed blood volume to reach the PLT target yield, the flow rate, and the acid citrate dextrose-A (ACD-A) volume used.
Platelet Yield Variables
After the PLT container had rested for 1 h without agitation, we obtained plateletpheresis yield samples with EDTA (2 ml) from the PLT bag for laboratory analysis. The yield was analyzed for volume, the numbers of WBC, red blood cells (RBC), and PLT, and swirling. Collection efficiency (CE) was calculated by the following formulas: CE = total PLT yield (10 11 ) × 100/(pre-apheresis PLT count + postapheresis PLT count/2) × blood volume processed (1) . Blood volume processed = TBV processed -ACD-A (ml) (2) .
Collection rate (CR) was calculated by the formula:
The ratio of PLT yield/blood volume processed was also calculated. Complete blood counts were determined using an automated blood cell counter (Sysmex XT 2000i, Roche diagnostics, Sysmex Corporation, Kobe, Japan), swirling was observed against light, and residual leukocyte concentrations in the PLT concentrate were determined by flow cytometry on a FACS Calibur (Becton Dickinson, Franklin Lakes, NJ, USA) in plateletpheresis yields.
Statistics
Data were expressed as the median (range) and mean ± standard deviation (SD 
Results
The general characteristics of in total 64 donors (n = 32 in the Amicus group and n = 32 in the COM.TEC group) are given in table 1. The median age of the donors was 28 (range, 18-43 years) and 29 years (range, 21-49 years) for the Amicus group and the COM.TEC group, respectively. While there were 29 males and 3 females in the Amicus group, there were 30 males and 2 females in the COM.TEC group. There was also no statistically significant difference between the two groups in terms of weight, height, and TBV of the donors.
Pre-and Post-Apheresis Peripheral Blood Variables
Pre-and post-apheresis PB data are shown in table 2. There were no significant differences in pre-apheresis Hb levels, Htc levels, and WBC counts. However, the pre-apheresis PLT count was significantly higher in patients on the COM.TEC instrument compared to the Amicus (198 × 10 3 /μl vs. 223 × 10 3 /μl; p = 0.035); no statistical differences in post-apheresis PB Hb and Htc levels were noted between the instruments. The post-apheresis PLT count was significantly lower in the Amicus compared to the COM.TEC group (144 × 10 3 /μl vs. 164 × 10 3 /μl; p = 0.019); there were, however, no statistically significant differences between the percentages of PLT and Hb loss (table 2) .
Plateletpheresis Operational Variables
The median blood volume processed to reach a PLT yield ≥ 3.3 × 10 11 was significantly higher with the COM.TEC compared to the Amicus (3,481 vs. 2,850 ml; p < 0.001). Additionally, the median flow rate of the Amicus was significantly higher than the median flow rate of the COM.TEC (65 vs. 58 ml/min; p < 0.001). Furthermore, there was a significantly higher median volume of ACD used in collections on the COM.TEC (373 vs. 300 ml; p < 0.001). However, the mean citrate load per minute was higher in the Amicus compared to the COM.TEC (6.6 ± 0.8 vs. 6.1 ± 0.5 ml/min) (p = 0.042). The median time needed for the procedures was also significantly longer with the COM.TEC (61 vs. 44 min; p < 0.001). The plateletpheresis procedure data are shown table 3.
Plateletpheresis Product Variables
The plateletpheresis product variables are summarized in table 4. There were no significant differences in terms of swirling percent, PLT yield/bag, and WBC count/bag (table 4) . However, PLT yield/blood volume processed was significantly higher with the Amicus (0.42 vs. 0.33; p < 0.001). The percentage of PLT yield ≥ 3.3 × 10 11 /bag was 91% (29/32) and 88% (28/32) on the Amicus and the COM.TEC instrument, respectively (p = 0.325). A CE of 55 ± 15% was obtained on the Amicus and 57 ± 15% on the COM.TEC (p = 0.477). However, the CR was statistically higher with the Amicus (0.077 ± 0.012 × 10 11 vs. 0.057 ± 0.008 × 10 11 PLT/min; p < 0.001). All products obtained with both instruments had WBC counts lower than 5 × 10 6 , as required. Additionally, the number of products with <1 × 10 6 WBC was 30 (94%) with the Amicus and 28 (87%) with the COM.TEC (p = 0.325).
Adverse Effects of Plateletpheresis
There were no high-rate adverse events that would cause early termination of the procedure. However, citrate-related mild toxicity occurred more commonly on the COM.TEC (6 donors) than on the Amicus (4 donors), due probably to the larger amounts of ACD-A used (300 vs. 373 ml; p < 0.001). All reactions responded rapidly to decreased flow rates and/or oral calcium supplementation.
Discussion
Although a variety of apheresis devices are currently available on the market for plateletpheresis procedures, there are scant data concerning plateletpheresis with the COM.TEC machine [13, 17, 18] . Additionally, there is no published data comparing the COM.TEC and the Amicus instruments used for platelet- pheresis. This study documents the features of the COM.TEC and compares it to the widely used Amicus instrument with respect to parameters such as separation time, PLT yield, CE, and WBC content. In today's world, productivity, i.e. 'doing more in less time', is as key a feature as yield when evaluating equipment. Coffe et al. [17] recorded the French experience on plateletpheresis with the COM.TEC cell separator; the blood volume processed was 4,606-5,229 l, and the mean separation time was between 87-109 min to reach a target PLT yield of 4.74 × 10 11 to 5.95 × 10 11 with the COM.TEC machine. Moog et al. [18] reported an average processed blood volume of 2,826 ± 409 ml in a donation time of 55 ± 11 min; the mean PLT yield of these products was 3.11 ± 0.40 × 10 11 . Strasser et al. [13] reported a processed blood volume of 2.49 ± 0.50 l and a mean separation time of 54 ± 13 min for a mean PLT yield of 2.90 ± 0.54 × 10 11 PLT using the COM.TEC. Burgstaler et al. [9] recorded median separation times of 77 min for a median PLT yield of 5.03 × 10 11 with the Amicus. Additionally, Benjamin et al. [10] reported average separation times of 71.5 min for median yields of 4.9 × 10 11 PLT using the Amicus. In this study, the median blood volume processed to reach a target PLT yield of 3.3 × 10 11 was significantly higher with the COM.TEC (3, COM.TEC (61 vs. 44 min; p < 0.001). On the other hand, they do report that sex, age, weight, TBV and pre-procedure PLT count affect PLT yield [13, 18] . In the present study, no significant differences were noted with regard to sex, age, weight, height and TBV between the two instruments; however, the median pre-procedure PLT counts were significantly different (198 × 10 3 /l vs. 223 × 10 3 /l; p = 0.035). This difference in the pre-apheresis PLT counts between the two groups may be due to insufficient numbers of donors per study arm as well as to performing in different subsequent time periods. Additionally, there was no statistically significant difference with respect to the median PLT yield of products per component between the separators (3.39 × 10 11 vs. 3.33 × 10 11 ; p = 0.185).
One important advantage of plateletpheresis is that no further manipulation is required for the product to be labeled as 'leukoreduced'. Leukocytes must be <5 × 10 6 per concentrate according to USA standards and <1 × 10 6 per concentrate according to European standards [14, 15] . Coffe et al. [17] reported that the residual leukocyte levels were <1 × 10 6 per concentrate (mean 0.233 ± 0.150 × 10 6 ) in more than 97% of the components produced (confidence interval (CI) of >95%). Moog et al. [18] recorded mean WBC contaminations of 0.11 ± 0.20 × 10 6 with the COM.TEC. Strasser et al. [13] reported that nearly all of the PLT products collected with the COM.TEC, the AS.TEC204, and the COBE spectra met the AABB standards as well as the more stringent European guidelines. Using the Amicus, Laurencet et al. [20] reported <5 × 10 6 WBC in 98% of the products and <1 × 10 6 WBC in 84%. Additionally, some studies have confirmed the consistency of leukoreduction [9] [10] [11] 21] . In the present study, all products obtained with both instruments had a WBC content <5 × 10 6 (0.30 × 10 6 to 1.2 × 10 6 vs. 0.26 × 10 6 to 1.43 × 10 6 ; p = 0.805). Additionally, the number of products with <1 × 10 6 WBC was 30 (94%) with the Amicus and 28 (87%) with the COM.TEC instrument (p = 0.325). Efficient PLT collection is an important issue when comparing instruments; the new generation of instruments appears to be more efficient [9] . In the present study, we noted a CE of 55 ± 15% with the Amicus and of 57 ± 15% with the COM.TEC (p = 0.477). Compared to results reported in the literature, our COM.TEC CE results (57 ± 15%) were similar to those reported: 52-55% [13, 17, 18] . However, our Amicus results (55 ± 15%) were lower than the reported averages of 66-73% [8] [9] [10] [11] [19] [20] [21] [22] . On the other hand, when comparing the instruments with regard to PLT yield/blood volume processed, the Amicus showed a significantly higher ratio compared to the COM.TEC (0.42 vs. 0.33; p < 0.001). Moreover, while the CR was statistically higher with the Amicus (0.077 ± 0.012 vs. 0.057 ± 0.008; p < 0.001), the CR of both machines was comparable to that reported in the literature [8, 9, 20, 23] . Efficient platelet collection with fewer procedure-related side effects is an important consideration for donors. The most common procedural adverse effects are citrate related [16] [17] [18] 24] ; the incidence of citrate toxicity varies from 0.11 to 16% in different studies [8, [25] [26] [27] [28] . Citrate-related reactions have been observed in 0.5% of cases on the COM.TEC machine [17] . Additionally, Benjamin et al. [10] reported that mild citrate-related toxicity occurred more commonly on the Amicus than on the Spectra LRS separator, as a result of the larger amount of ACD used (483 vs. 389 ml; p < 0.0001). However, these adverse reactions were successfully treated by reducing the ACD infusion rate, the amount of ACD used and/or oral calcium supplementation [13, 17, 18] . In the present study, since there were significant differences between the flow rates of the devices, separation time and ACD consumption were also found to be statistically significant (p < 0.001). Additionally, there were statistically significant differences between the two groups in terms of the citrate load per minute (p = 0.042). The higher ACD consumption but lower citrate load per minute of the COM.TEC procedure may be explained with the low number of donors per arm. Citrate-related mild toxicity occurred more commonly on the COM.TEC (6 donors) than on the Amicus (4 donors). However, this was not clinically significant.
In conclusion, both instruments perform plateletpheresis efficiently. Additionally, consistent leukoreduction was obtained with both machines. The Amicus, however, has the advantage of a lower separation time.
